Artwork

Content provided by esanum. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by esanum or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !

Pipeline! Medikamentenzulassungen und Pharmanews Juli/August 2020

14:04
 
Distribuie
 

Manage episode 314040556 series 3129175
Content provided by esanum. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by esanum or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

Der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Zulassungsbehörde (EMA) hat im Juli 2020 drei neue Substanzen für die Behandlung von Krebserkrankungen zur Zulassung empfohlen. Außerdem empfahl er einen monoklonalen Antikörper für Patienten mit Sichelzellenkrankheit und einen weiteren JAK-Hemmer für die Behandlung der rheumatoiden Arthritis. Im August tagte der Ausschuss nicht. Mit der Zulassung dieser Substanzen ist bis spätestens Ende September zu rechnen. (C) esanum.de

  continue reading

60 episoade

Artwork
iconDistribuie
 
Manage episode 314040556 series 3129175
Content provided by esanum. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by esanum or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

Der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Zulassungsbehörde (EMA) hat im Juli 2020 drei neue Substanzen für die Behandlung von Krebserkrankungen zur Zulassung empfohlen. Außerdem empfahl er einen monoklonalen Antikörper für Patienten mit Sichelzellenkrankheit und einen weiteren JAK-Hemmer für die Behandlung der rheumatoiden Arthritis. Im August tagte der Ausschuss nicht. Mit der Zulassung dieser Substanzen ist bis spätestens Ende September zu rechnen. (C) esanum.de

  continue reading

60 episoade

Toate episoadele

×
 
Loading …

Bun venit la Player FM!

Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.

 

Ghid rapid de referință